Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSurgical Innovations Regulatory News (SUN)

Share Price Information for Surgical Innovations (SUN)

Share Price is delayed by 15 minutes
Get Live Data
0.475    0.00 (0.00%)
Bid:
0.45
Ask:
0.50
Spread: 0.05 (11.111%)
Market Cap: £4.43m
SUN Live PriceLast checked at - London Stock Exchange

Intraday Surgical Innovations Share Chart

Director/PDMR Shareholding

17 Feb 2012 16:36

RNS Number : 6740X
Surgical Innovations Group PLC
17 February 2012
 



17 February 2012

Surgical Innovations Group plc

("SI" or the "Company")

 

Directors' Dealings

 

Surgical Innovations Group plc (AIM: SUN), the designer and manufacturer of innovative medical devices, announces that it received notification today on Friday 17 February 2012 Graham Bowland, Chief Executive Officer of the Company, sold 5,889,000 shares at price of 10.5 pence per share.

 

Following the sale, Graham Bowland is interested in 4,528,498 common shares representing approximately 1.12% of the common shares in issue, and also holds options over 1,400,000 shares.

 

The sale has been undertaken as a one off transaction for personal reasons, to enable Graham Bowland to make a property purchase. Graham continues to be a significant holder in the Company, and his long term commitment to the business remains unchanged.

 

- Ends -

Enquiries:

 

Surgical Innovations Group plc

www.sigroupplc.com

Doug Liversidge, Non-Executive Chairman

Graham Bowland, Chief Executive Officer

Tel: +44 (0) 113 230 7597 or graham.bowland@surginno.co.uk

Seymour Pierce Limited

www.seymourpierce.com

Freddy Crossley / Sarah Jacobs

Tel: +44 (0) 20 7107 8000

Corporate Broking

David Banks/ Jacqui Briscoe

Walbrook PR Ltd

Tel: +44 (0) 20 7933 8780

Paul McManus

Mob: 07980 541 893 or paul.mcmanus@walbrookpr.com

Fiona Henson

Mob: 07886 335 992 or fiona.henson@walbrookpr.com

 

 

 

Notes to Editors:

 

About Surgical Innovations Group plc

 

Surgical Innovations Group plc specialises in the design and manufacture of innovative devices for use in minimally invasive surgery (MIS) and industrial markets.

 

As well as manufacturing single-use and reusable instruments for the laparoscopic market, the Group has pioneered its flagship Resposable® instrumentation combining both single use and reusable components, ensuring ongoing revenue streams and delivering the optimum procedure performance to cost ratio.

 

Over 100 people are employed at the Group's 32,000 square feet facility in Leeds, with in-house design, plastic injection moulding and manufacturing equipment, producing products to the highest quality standards.

 

The Group's patented products are sold through three main channels:

 

SI brand

Through an established network of 45 distribution partners, Surgical Innovations branded products are sold in all major medical markets including North America, Europe, South Africa, the Middle East, South-east Asia and Australia.

 

OEM and IP

The Group supplies large medical device companies on an OEM basis, collecting sales fees as well as IP license and royalty fees. Clients include Teleflex Medical, Gyrus and CareFusion.

 

Industrial

 

SI's patented segment technology has been applied to the industrial market enabling customers to undertake inspection and maintenance of large-scale equipment, such as turbines, in situ with minimum disassembly and downtime.

 

For more information, see www.surginno.com

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSBLGDDSXBBGDR
Date   Source Headline
5th Jun 20267:00 amRNSNotice of AGM & Posting of Annual Report &Accounts
21st Apr 20267:00 amRNSFinal Results
9th Apr 20267:00 amRNSNotice of Results and Investor Presentation
8th Jan 20267:00 amRNSChief Financial Officer update
18th Dec 20257:00 amRNSTrading Update
28th Nov 20257:00 amRNSNew LTIP & Grant of Options
29th Sep 20257:05 amRNSBoard Changes
29th Sep 20257:00 amRNSHalf-year Report
17th Sep 20253:15 pmRNSNotice of Results
27th Jun 20254:42 pmRNSResult of AGM
26th Jun 202511:36 amRNSWithdrawal of AGM Resolutions 9 and 10
4th Jun 20258:00 amRNSNotice of AGM & Posting of Annual Report &Accounts
30th May 20257:00 amRNSFinal Results
10th Apr 20257:00 amRNSTrading update
1st Apr 202511:30 amRNSUpdate on timing of 2024 Full Year results
19th Feb 202510:11 amRNSHolding(s) in Company
17th Feb 20254:12 pmRNSHolding(s) in Company
12th Feb 20257:00 amRNSFY24 Trading Update & & Directorship Change
30th Sep 20247:00 amRNSHalf-year Report
10th Sep 20247:00 amRNSNotice of Results
27th Aug 20243:51 pmRNSHolding(s) in Company
27th Aug 20243:49 pmRNSHolding(s) in Company
19th Aug 20241:06 pmRNSHolding(s) in Company
19th Aug 20241:01 pmRNSHolding(s) in Company
29th Jul 202412:18 pmRNSHolding(s) in Company
25th Jul 20244:04 pmRNSHolding(s) in Company
17th Jun 20244:43 pmRNSResult of AGM
10th Jun 20247:00 amRNSDirectorate Change - Appointment of CFO
23rd May 20247:00 amRNSNotice of AGM and Posting of Annual Report
22nd Apr 20243:34 pmRNSHolding(s) in Company
19th Apr 20246:25 pmRNSHolding(s) in Company
18th Apr 20247:01 amRNSFinal Results
18th Apr 20247:00 amRNSNew exclusive UK distribution agreements secured
9th Apr 20247:00 amRNSDirectorate Change & Notice of Results
29th Jan 20247:00 amRNSYear-end 2023 Trading Update
19th Dec 20237:00 amRNSDirectorate Change
5th Dec 20237:00 amRNSDirectorate Change
19th Sep 20237:00 amRNSHalf-year Report
6th Sep 20237:00 amRNSTrading Update and Notice of Results
27th Jun 202312:12 pmRNSResult of AGM
27th Jun 20237:00 amRNSAGM Statement
26th May 20237:00 amRNSNotice of AGM and Posting of Annual Report
25th May 202311:11 amRNSDirector/PDMR Shareholding - Replacement
25th May 20237:00 amRNSDirector/PDMR Shareholding
22nd May 20237:00 amRNSDirectorate changes and board succession planning
29th Mar 20237:00 amRNSFinal Results
3rd Mar 20237:00 amRNSNotice of Results and Investor Presentation
23rd Jan 20237:00 amRNSYear-end Trading Update
21st Sep 20227:00 amRNSHalf-year Report
2nd Sep 20227:00 amRNSNotice of Interim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.